文献速递临床试验与 GCP基础与转化研究

合生元补充剂对危重脓毒症患儿炎症指标影响的随机对照试验方案研究

Investigating the effect of synbiotic supplementation on inflammatory indices in critically ill septic children: a protocol study for randomized control trial.
PubMed 文献 · Trials · 2024-10-24

该随机对照试验方案拟纳入54例脓毒症患儿,随机分为合生元组或安慰剂组,合生元KidiLact含十种益生菌株和益生元低聚果糖,每日两袋共7天,经口或鼻胃管给药,评估白介素-6、肿瘤坏死因子α、C反应蛋白和红细胞沉降率等炎症指标及临床结局。

要点

  • 54例脓毒症患儿随机接受合生元KidiLact或安慰剂,每日两袋共7天。
  • 合生元含十种益生菌株和益生元低聚果糖,口服或鼻胃管给药。
  • 主要评估炎症因子包括IL-6、TNF-α、CRP和ESR及临床结局。

核心结论

  • 该随机临床试验旨在评估合生元补充对儿科重症监护病房脓毒症患儿炎症标志物和临床结局的影响。
  • 作者认为若关于益生菌效果的预期正确,合生元可作为改善医院内儿科脓毒症病情的具有成本效益的补充剂。

研究设计与样本

  • 随机对照试验方案,拟纳入54例符合条件的脓毒症患者,随机分配至合生元组或安慰剂组。
  • 合生元补充剂KidiLact含十种益生菌株和益生元低聚果糖,参与者每日接受两袋,持续7天,与无菌水混合后经口或鼻胃管给药。
  • 将评估炎症因子包括白介素-6(IL-6)、肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)和红细胞沉降率(ESR),并进行人体测量、营养评估、生化分析和临床评估以评估治疗结局。
  • 使用SPSS 19版进行统计分析,显著性水平为P<.05。
  • 试验注册号IRCT20230523058266N1,注册日期2023年10月30日。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sepsis, a severe inflammatory response to infection, is a global health priority due to its high mortality and long-term disability rates. Its pathophysiology involves both inflammation and immune suppression. Managing sepsis requires significant healthcare resources and expenditure, with sepsis being a leading cause of hospital costs. Gut microbiotas play a crucial role in sepsis, and probiotics show promise in managing it by restoring microbial balance. Despite advances, targeted therapies for sepsis remain elusive, necessitating innovative approaches such as probiotic therapy. METHOD: Fifty-four eligible patients with sepsis will be randomly assigned to either the synbiotic or placebo group. The synbiotic supplement, KidiLact, comprises ten probiotic strains and prebiotic fructooligosaccharides. Participants will receive two sachets daily for 7 days, mixed with sterile water and administered orally or via gavage. Inflammatory factors including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) will be evaluated. Anthropometric measurements, nutritional assessment, biochemical analysis, and clinical evaluation will be conducted to assess treatment outcomes. Statistical analysis will be performed to compare results between the two groups, employing SPSS version 19 with a significance level of P < .05. CONCLUSION: This randomized clinical trial aims to evaluate synbiotic supplementation effects on inflammatory markers and clinical outcomes in pediatric sepsis patients in the pediatric intensive care unit (PICU). Probiotics have shown promise in reducing proinflammatory cytokines like IL-6, TNF-α, and CRP, which are vital in the inflammatory response. Synbiotics can enhance gut integrity, preventing pathogen translocation and reducing inflammation. If our expectations regarding the effects of probiotics are correct, we can use them as a cost-effective supplement to improve the condition of pediatric sepsis in hospitals. TRIAL REGISTRATION: IRCT,IRCT20230523058266N1 Registered 30 October 2023, https://irct.behdasht.gov.ir/trial/71397 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chamani A, Mashhadi F, Khademi G, et al. Investigating the effect of synbiotic supplementation on inflammatory indices in critically ill septic children: a protocol study for randomized control trial. Trials. 2024. PMID: 39443948. doi:10.1186/s13063-024-08514-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。